IP Library Granted Patent US 9,545,445
Granted Patent B2
US 9,545,445 · App. 12/823,715 · Granted Jan 17, 2017

Therapeutic drug for hypertension or prehypertension

Inventors: Takashi Shirakura (Hino, JP); Mizuho Tamura (Hino, JP); Yoshimasa Takahashi (Hino, JP); Ippei Kuwahara (Sagamihara, JP)
Assignee: Teijin Pharma Limited
A61K45/06A61K31/426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,545,445
App. No.
12/823,715
Granted
Jan 17, 2017
Kind
B2
Abstract

The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.

Claims (6)

1. A therapeutic method for hypertension or high-normal blood pressure comprising administering (a) and (b) in an amount which is more effective than an additive effect for the therapy of hypertension or high-normal blood pressure to a patient in need thereof:

(a) 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid or a pharmaceutically acceptable salt thereof,

(b) losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, pratosartan, eprosartan or a pharmaceutically acceptable salt thereof.

2. The therapeutic method for hypertension or high-normal blood pressure according to claim 1 , wherein (b) is losartan or candesartan.

3. The therapeutic method for hypertension or high-normal blood pressure according to claim 1 , wherein (a) and (b) are administered simultaneously.

4. The therapeutic method for hypertension or high-normal blood pressure according claim 1 , wherein (a) and (b) are administered separately.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 043931/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2010
From: SHIRAKURA, TAKASHI; TAMURA, MIZUHO; TAKAHASHI, YOSHIMASA; KUWAHARA, IPPEI
To: TEIJIN PHARMA LIMITED
Reel/Frame 025416/0707 →
Continuity (2)
Provisional Application 61220717 · Jun 26, 2009
Related Publication 20110046192A1 · Feb 24, 2011